1-3 of 3
Miroslav Ravic, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Achim Rothe, MD, Stephanie Sasse, MD, Max S. Topp, MD, Dennis A. Eichenauer, MD, Bastian von Tresckow, MD, Horst-Dieter Hummel, MD, Miroslav Ravic, MD PhD, Jens-Peter Marschner, MD, Andreas Engert, MD
Journal: Blood
Blood (2014) 124 (21): 1753.
https://doi.org/10.1182/blood.V124.21.1753.1753
Published: 2014
Journal Articles

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Eugene Zhukovsky, PhD, Achim Rothe, MD, Bastian von Tresckow, MD, Max Topp, Anas Younes, MD, Dennis A. Eichenauer, MD, Horst Hummel, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Joerg Kessler, PhD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Poggevon Strandmann, PhD, Andreas Engert, MD
Journal: Blood
Blood (2013) 122 (21): 5116.
https://doi.org/10.1182/blood.V122.21.5116.5116
Published: 2013
Journal Articles

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Achim Rothe, MD, Anas Younes, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Dennis A. Eichenauer, MD, Joerg Kessler, Max S. Topp, MD, Horst Hummel, MD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Pogge von Strandmann, PhD, Andreas Engert, MD
Journal: Blood
Blood (2011) 118 (21): 3709.
https://doi.org/10.1182/blood.V118.21.3709.3709
Published: 2011